{
    "schema": 1,
    "fid": "foundayo-gets-an-ema-green-light-but-comes-next",
    "type": "article",
    "object_id": 22265,
    "title": "Foundayo gets an EMA green light, but what comes next",
    "entity": "Foundayo gets an EMA green light, but what comes next",
    "url": "https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next",
    "facts_url": "https://www.preppinpeppers.com/facts/foundayo-gets-an-ema-green-light-but-comes-next",
    "currency": null,
    "tldr": "On 15 October 2026 EMA's medicines committee (the CHMP) recommended authorising Foundayo (orforglipron) for type 2 diabetes and weight management; the",
    "facts": [
        {
            "id": "foundayo-gets-an-ema-green-light-but-comes-next:title",
            "category": "identity",
            "entity": "Foundayo gets an EMA green light, but what comes next",
            "attribute": "title",
            "value": "Foundayo gets an EMA green light, but what comes next",
            "source": "Lab article (https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next)",
            "evidence": "https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next"
        },
        {
            "id": "foundayo-gets-an-ema-green-light-but-comes-next:published",
            "category": "identity",
            "entity": "Foundayo gets an EMA green light, but what comes next",
            "attribute": "published",
            "value": "2026-10-19",
            "source": "Lab article (https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next)",
            "evidence": "https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next"
        },
        {
            "id": "foundayo-gets-an-ema-green-light-but-comes-next:author",
            "category": "identity",
            "entity": "Foundayo gets an EMA green light, but what comes next",
            "attribute": "author",
            "value": "PreppinPeppers Editorial Team",
            "source": "Lab article (https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next)",
            "evidence": "https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next"
        },
        {
            "id": "foundayo-gets-an-ema-green-light-but-comes-next:topics",
            "category": "identity",
            "entity": "Foundayo gets an EMA green light, but what comes next",
            "attribute": "topics",
            "value": "News, peptide news, research news",
            "source": "Lab article (https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next)",
            "evidence": "https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next"
        },
        {
            "id": "foundayo-gets-an-ema-green-light-but-comes-next:summary",
            "category": "content",
            "entity": "Foundayo gets an EMA green light, but what comes next",
            "attribute": "summary",
            "value": "On 15 October 2026 EMA's medicines committee (the CHMP) recommended authorising Foundayo (orforglipron) for type 2 diabetes and weight management; the",
            "source": "Lab article (https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next)",
            "evidence": "https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next"
        },
        {
            "id": "foundayo-gets-an-ema-green-light-but-comes-next:section-1",
            "category": "content",
            "entity": "Foundayo gets an EMA green light, but what comes next",
            "attribute": "section",
            "value": "What did EMA's medicines committee recommend for Foundayo?",
            "source": "Lab article (https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next)",
            "evidence": "https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next"
        },
        {
            "id": "foundayo-gets-an-ema-green-light-but-comes-next:section-2",
            "category": "content",
            "entity": "Foundayo gets an EMA green light, but what comes next",
            "attribute": "section",
            "value": "What is confirmed, and what is still open?",
            "source": "Lab article (https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next)",
            "evidence": "https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next"
        },
        {
            "id": "foundayo-gets-an-ema-green-light-but-comes-next:section-3",
            "category": "content",
            "entity": "Foundayo gets an EMA green light, but what comes next",
            "attribute": "section",
            "value": "What does the published trial data show?",
            "source": "Lab article (https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next)",
            "evidence": "https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next"
        },
        {
            "id": "foundayo-gets-an-ema-green-light-but-comes-next:section-4",
            "category": "content",
            "entity": "Foundayo gets an EMA green light, but what comes next",
            "attribute": "section",
            "value": "What do people get wrong about this news, and what are the documented risks of untested product?",
            "source": "Lab article (https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next)",
            "evidence": "https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next"
        },
        {
            "id": "foundayo-gets-an-ema-green-light-but-comes-next:product-gansulin-metal-peptide-pen",
            "category": "products",
            "entity": "Foundayo gets an EMA green light, but what comes next",
            "attribute": "references product",
            "value": "Gansulin Pen · Reusable Click-Dial, 3 ml (1-60 Units)",
            "source": "Lab article (https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next)",
            "evidence": "https://www.preppinpeppers.com/products/gansulin-metal-peptide-pen"
        },
        {
            "id": "foundayo-gets-an-ema-green-light-but-comes-next:product-gansulin-3ml-cartridge",
            "category": "products",
            "entity": "Foundayo gets an EMA green light, but what comes next",
            "attribute": "references product",
            "value": "Gansulin-Compatible 3 ml Glass Cartridge for Pens (10-Pack)",
            "source": "Lab article (https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next)",
            "evidence": "https://www.preppinpeppers.com/products/gansulin-3ml-cartridge"
        },
        {
            "id": "foundayo-gets-an-ema-green-light-but-comes-next:product-bacteriostatic-water-30ml",
            "category": "products",
            "entity": "Foundayo gets an EMA green light, but what comes next",
            "attribute": "references product",
            "value": "Bacteriostatic Water 30 ml Multi-Dose Vial (Pfizer Hospira, USP)",
            "source": "Lab article (https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next)",
            "evidence": "https://www.preppinpeppers.com/products/bacteriostatic-water-30ml"
        },
        {
            "id": "foundayo-gets-an-ema-green-light-but-comes-next:source-pubmed-ncbi-nlm-nih-gov",
            "category": "source",
            "entity": "Foundayo gets an EMA green light, but what comes next",
            "attribute": "cites",
            "value": "Liu et al., Am J Manag Care 2025: Navigating compounded semaglutide: what health care providers need to know - pubmed.ncbi.nlm.nih.gov",
            "source": "Lab article (https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next)",
            "evidence": "https://pubmed.ncbi.nlm.nih.gov/40966636/"
        },
        {
            "id": "foundayo-gets-an-ema-green-light-but-comes-next:source-pubmed-ncbi-nlm-nih-gov-2",
            "category": "source",
            "entity": "Foundayo gets an EMA green light, but what comes next",
            "attribute": "cites",
            "value": "Wharton et al., N Engl J Med 2025: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment - pubmed.ncbi.nlm.nih.gov",
            "source": "Lab article (https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next)",
            "evidence": "https://pubmed.ncbi.nlm.nih.gov/40960239/"
        },
        {
            "id": "foundayo-gets-an-ema-green-light-but-comes-next:source-pubmed-ncbi-nlm-nih-gov-3",
            "category": "source",
            "entity": "Foundayo gets an EMA green light, but what comes next",
            "attribute": "cites",
            "value": "McCall et al., Expert Opin Drug Saf 2026: Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system - pubmed.ncbi.nlm.nih.gov",
            "source": "Lab article (https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next)",
            "evidence": "https://pubmed.ncbi.nlm.nih.gov/40285721/"
        },
        {
            "id": "foundayo-gets-an-ema-green-light-but-comes-next:source-pubchem-ncbi-nlm-nih-gov",
            "category": "source",
            "entity": "Foundayo gets an EMA green light, but what comes next",
            "attribute": "cites",
            "value": "NCBI PubChem CID 137319706: Orforglipron (C48H48F2N10O5) - pubchem.ncbi.nlm.nih.gov",
            "source": "Lab article (https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next)",
            "evidence": "https://pubchem.ncbi.nlm.nih.gov/compound/137319706"
        },
        {
            "id": "foundayo-gets-an-ema-green-light-but-comes-next:source-www-ema-europa-eu",
            "category": "source",
            "entity": "Foundayo gets an EMA green light, but what comes next",
            "attribute": "cites",
            "value": "European Medicines Agency (EMA): Foundayo - medicine overview (CHMP opinion) (retrieved 2026-10-19) - www.ema.europa.eu",
            "source": "Lab article (https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next)",
            "evidence": "https://www.ema.europa.eu/en/medicines/human/EPAR/foundayo"
        },
        {
            "id": "foundayo-gets-an-ema-green-light-but-comes-next:source-www-ema-europa-eu-2",
            "category": "source",
            "entity": "Foundayo gets an EMA green light, but what comes next",
            "attribute": "cites",
            "value": "European Medicines Agency (EMA): New oral GLP-1 medicine for weight management and type 2 diabetes (retrieved 2026-10-19) - www.ema.europa.eu",
            "source": "Lab article (https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next)",
            "evidence": "https://www.ema.europa.eu/en/news/new-oral-glp-1-medicine-weight-management-type-2-diabetes"
        }
    ],
    "buy": [],
    "faq": [
        {
            "q": "What did EMA recommend for Foundayo?",
            "a": "EMA said the CHMP adopted a positive opinion on 15 October 2026, recommending a marketing authorisation for Foundayo (orforglipron) for type 2 diabetes and for weight management."
        },
        {
            "q": "Is Foundayo approved in the EU yet?",
            "a": "EMA's overview says the summary of product characteristics will be published after the European Commission grants the marketing authorisation. The committee opinion is a recommendation, not the grant."
        },
        {
            "q": "What is orforglipron?",
            "a": "EMA describes the active substance as a small, non-peptide molecule that activates the GLP-1 receptor. PubChem lists its formula as C48H48F2N10O5 and its molecular weight as 883.0."
        },
        {
            "q": "Who is the applicant for Foundayo?",
            "a": "According to EMA's medicine overview, the applicant is Eli Lilly Nederland B.V."
        },
        {
            "q": "What side effects does EMA list for Foundayo?",
            "a": "EMA's overview says the most common side effects are gastrointestinal, such as nausea, vomiting and diarrhoea."
        },
        {
            "q": "What did the phase 3 orforglipron trial examine?",
            "a": "Wharton and colleagues (NEJM, 2025) ran a randomized, double-blind trial over 72 weeks in adults with obesity without diabetes. The primary end point was percent change in body weight from baseline."
        },
        {
            "q": "Do adverse-event reports show a product caused harm?",
            "a": "No. A report records that an event was mentioned alongside a product. It does not prove the product caused the event."
        },
        {
            "q": "Is orforglipron a peptide?",
            "a": "No. EMA calls it a small, non-peptide molecule, and the 2025 NEJM abstract describes it as nonpeptide."
        }
    ],
    "jsonld": [
        {
            "@context": "https://schema.org",
            "@type": "Article",
            "headline": "Foundayo gets an EMA green light, but what comes next",
            "url": "https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next",
            "mainEntityOfPage": "https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next",
            "datePublished": "2026-10-19",
            "dateModified": "2026-10-19",
            "author": {
                "@type": "Person",
                "name": "PreppinPeppers Editorial Team"
            },
            "publisher": {
                "@type": "Organization",
                "name": "PreppinPeppers"
            },
            "description": "On 15 October 2026 EMA's medicines committee (the CHMP) recommended authorising Foundayo (orforglipron) for type 2 diabetes and weight management; the"
        },
        {
            "@context": "https://schema.org",
            "@type": "FAQPage",
            "url": "https://www.preppinpeppers.com/facts/foundayo-gets-an-ema-green-light-but-comes-next",
            "mainEntity": [
                {
                    "@type": "Question",
                    "name": "What did EMA recommend for Foundayo?",
                    "acceptedAnswer": {
                        "@type": "Answer",
                        "text": "EMA said the CHMP adopted a positive opinion on 15 October 2026, recommending a marketing authorisation for Foundayo (orforglipron) for type 2 diabetes and for weight management."
                    }
                },
                {
                    "@type": "Question",
                    "name": "Is Foundayo approved in the EU yet?",
                    "acceptedAnswer": {
                        "@type": "Answer",
                        "text": "EMA's overview says the summary of product characteristics will be published after the European Commission grants the marketing authorisation. The committee opinion is a recommendation, not the grant."
                    }
                },
                {
                    "@type": "Question",
                    "name": "What is orforglipron?",
                    "acceptedAnswer": {
                        "@type": "Answer",
                        "text": "EMA describes the active substance as a small, non-peptide molecule that activates the GLP-1 receptor. PubChem lists its formula as C48H48F2N10O5 and its molecular weight as 883.0."
                    }
                },
                {
                    "@type": "Question",
                    "name": "Who is the applicant for Foundayo?",
                    "acceptedAnswer": {
                        "@type": "Answer",
                        "text": "According to EMA's medicine overview, the applicant is Eli Lilly Nederland B.V."
                    }
                },
                {
                    "@type": "Question",
                    "name": "What side effects does EMA list for Foundayo?",
                    "acceptedAnswer": {
                        "@type": "Answer",
                        "text": "EMA's overview says the most common side effects are gastrointestinal, such as nausea, vomiting and diarrhoea."
                    }
                },
                {
                    "@type": "Question",
                    "name": "What did the phase 3 orforglipron trial examine?",
                    "acceptedAnswer": {
                        "@type": "Answer",
                        "text": "Wharton and colleagues (NEJM, 2025) ran a randomized, double-blind trial over 72 weeks in adults with obesity without diabetes. The primary end point was percent change in body weight from baseline."
                    }
                },
                {
                    "@type": "Question",
                    "name": "Do adverse-event reports show a product caused harm?",
                    "acceptedAnswer": {
                        "@type": "Answer",
                        "text": "No. A report records that an event was mentioned alongside a product. It does not prove the product caused the event."
                    }
                },
                {
                    "@type": "Question",
                    "name": "Is orforglipron a peptide?",
                    "acceptedAnswer": {
                        "@type": "Answer",
                        "text": "No. EMA calls it a small, non-peptide molecule, and the 2025 NEJM abstract describes it as nonpeptide."
                    }
                }
            ]
        }
    ],
    "dates": {
        "published": "2026-10-19",
        "modified": "2026-10-19"
    }
}